DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies" report to their offering.
Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence - it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.
The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.
The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-systemic conditions, as the market is currently predominantly composed of therapies that symptomatically treat the condition, or at best slow disease progression. However, as the understanding of disease pathophysiology in both diabetes and its complications increases, new targets are being identified and converted into improved therapeutic options that are better aligned with the underlying disease pathophysiology than their predecessors.
The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market. One innovative therapy is CBX-129801, a promising synthetic peptide that is currently in development for diabetic neuropathy. Innovation can also be seen within diabetic retinopathy, with therapies such as BCN070660, a topical ophthalmologic formulation currently in development.
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
2.1 Significant Unmet Needs in Diabetic Complications Market
2.2 High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications
2.3 Deal Activity Varies with First-in-Class Status
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Diabetes Mellitus Overview
4.2 Diabetic Neuropathies
4.3 Diabetic Nephropathy
4.4 Diabetic Retinopathies
4.5 Overview of Marketed Products in Diabetic Complications
5 Assessment of Pipeline Product Innovation
5.1 Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target
5.2 Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target
5.3 Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target
6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Metabolic Disorders
6.2 First-in-Class Matrix Assessment
7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting NADPH Oxidase 4
7.2 Pipeline Programs Targeting Glutamate Decarboxylase
7.3 Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1
7.4 Pipeline Programs Targeting Motilin Receptor
7.5 Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1
7.6 Pipeline Programs Targeting Leukotriene B4 Receptor 1
7.7 Pipeline Programs Targeting Integrin Alpha V
7.8 Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4
8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals
9 Appendix
For more information visit http://www.researchandmarkets.com/research/grp6gk/frontier_pharma
